How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aflibercept-folfiri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

aflibercept + FOLFIRI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

aflibercept + FOLFIRI (aflibercept + FOLFIRI) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (fusion protein) + chemotherapy combination. Area: Oncology.

marketed VEGF inhibitor (fusion protein) + chemotherapy combination VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

aflibercept + FOLFIRI (aflibercept + FOLFIRI) — CR-CSSS Champlain-Charles-Le Moyne. Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
aflibercept + FOLFIRI TARGET	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
Aflibercept-mFOLFIRI3	Aflibercept-mFOLFIRI3	Hôpital Franco-Britannique-Fondation Cognacq-Jay	phase 3	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF (vascular endothelial growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (fusion protein) + chemotherapy combination class)

CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class
Hôpital Franco-Britannique-Fondation Cognacq-Jay · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aflibercept + FOLFIRI — Competitive Intelligence Brief. https://druglandscape.com/ci/aflibercept-folfiri. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab